{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:31:44Z","timestamp":1789500704007,"version":"build-2803163510"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"35","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172782"],"award-info":[{"award-number":["82172782"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005046","name":"Natural Science Foundation of Heilongjiang Province","doi-asserted-by":"publisher","award":["LH2021H040"],"award-info":[{"award-number":["LH2021H040"]}],"id":[{"id":"10.13039\/501100005046","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010722","name":"Harbin Medical University","doi-asserted-by":"publisher","award":["HMUMIF-22007"],"award-info":[{"award-number":["HMUMIF-22007"]}],"id":[{"id":"10.13039\/100010722","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2025,9,15]]},"DOI":"10.1038\/s41388-025-03482-1","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T09:59:56Z","timestamp":1751623196000},"page":"3199-3212","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Increased antiandrogen enzalutamide sensitivity via altering prostate cancer stem cell traits through modulating the androgen receptor-mediated CDR1\/circCDR1-AS\/miR-1290\/BMP4 signaling"],"prefix":"10.1038","volume":"44","author":[{"given":"Diwei","family":"Huo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minggui","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxue","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donglong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengxing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinguo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruicong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfeng","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuebin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xunwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengbo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huike","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8709-9168","authenticated-orcid":false,"given":"Keliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"key":"3482_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3482_CR2","doi-asserted-by":"crossref","unstructured":"Zheng Z, Li J, Liu Y, Shi Z, Xuan Z, Yang K et al. The crucial role of AR-V7 in enzalutamide-resistance of castration-resistant prostate cancer. Cancers. 2022;14:4877.","DOI":"10.3390\/cancers14194877"},{"key":"3482_CR3","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/s41585-020-0298-8","volume":"17","author":"M Carceles-Cordon","year":"2020","unstructured":"Carceles-Cordon M, Kelly WK, Gomella L, Knudsen KE, Rodriguez-Bravo V, Domingo-Domenech J. Cellular rewiring in lethal prostate cancer: the architect of drug resistance. Nat Rev Urol. 2020;17:292\u2013307.","journal-title":"Nat Rev Urol"},{"key":"3482_CR4","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/ncponc0168","volume":"2","author":"H Miyamoto","year":"2005","unstructured":"Miyamoto H, Messing EM, Chang C. Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer?. Nat Clin Pr Oncol. 2005;2:236\u20137.","journal-title":"Nat Clin Pr Oncol"},{"key":"3482_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s13046-022-02287-4","volume":"41","author":"D Chen","year":"2022","unstructured":"Chen D, Chou FJ, Chen Y, Huang CP, Tian H, Wang Y, et al. Targeting the radiation-induced ARv7-mediated circNHS\/miR-512-5p\/XRCC5 signaling with Quercetin increases prostate cancer radiosensitivity. J Exp Clin Cancer Res. 2022;41:235.","journal-title":"J Exp Clin Cancer Res"},{"key":"3482_CR6","doi-asserted-by":"crossref","unstructured":"\u00d6zg\u00fcn F, Kaya Z, Morova T, Geverts B, Abraham TE, Houtsmuller AB et al. DNA binding alters ARv7 dimer interactions. J Cell Sci. 2021;134:jcs258332.","DOI":"10.1242\/jcs.258332"},{"key":"3482_CR7","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1158\/2159-8290.CD-13-0226","volume":"3","author":"JD Joseph","year":"2013","unstructured":"Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D, et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov. 2013;3:1020\u20139.","journal-title":"Cancer Discov"},{"key":"3482_CR8","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/pros.23134","volume":"76","author":"R Tummala","year":"2016","unstructured":"Tummala R, Nadiminty N, Lou W, Evans CP, Gao AC. Lin28 induces resistance to anti-androgens via promotion of AR splice variant generation. Prostate. 2016;76:445\u201355.","journal-title":"Prostate"},{"key":"3482_CR9","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.eururo.2017.04.005","volume":"72","author":"R Wang","year":"2017","unstructured":"Wang R, Sun Y, Li L, Niu Y, Lin W, Lin C, et al. Preclinical study using Malat1 small interfering RNA or androgen receptor splicing variant 7 degradation enhancer ASC-J9(\u00ae) to suppress enzalutamide-resistant prostate cancer progression. Eur Urol. 2017;72:835\u201344.","journal-title":"Eur Urol"},{"key":"3482_CR10","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s13402-023-00803-y","volume":"46","author":"S Dahal","year":"2023","unstructured":"Dahal S, Chaudhary P, Kim JA. Induction of promyelocytic leukemia zinc finger protein by miR-200c-3p restores sensitivity to anti-androgen therapy in androgen-refractory prostate cancer and inhibits the cancer progression via down-regulation of integrin \u03b13\u03b24. Cell Oncol. 2023;46:1113\u201326.","journal-title":"Cell Oncol"},{"key":"3482_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.978","volume":"12","author":"UG Lo","year":"2022","unstructured":"Lo UG, Chen YA, Cen J, Deng S, Luo J, Zhau H, et al. The driver role of JAK-STAT signalling in cancer stemness capabilities leading to new therapeutic strategies for therapy- and castration-resistant prostate cancer. Clin Transl Med. 2022;12:e978.","journal-title":"Clin Transl Med"},{"key":"3482_CR12","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1158\/0008-5472.CAN-15-1542","volume":"76","author":"V Catalano","year":"2016","unstructured":"Catalano V, Dentice M, Ambrosio R, Luongo C, Carollo R, Benfante A, et al. Activated thyroid hormone promotes differentiation and chemotherapeutic sensitization of colorectal cancer stem cells by regulating Wnt and BMP4 signaling. Cancer Res. 2016;76:1237\u201344.","journal-title":"Cancer Res"},{"key":"3482_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/onc.2013.54","volume":"33","author":"YX Fang","year":"2014","unstructured":"Fang YX, Gao WQ. Roles of microRNAs during prostatic tumorigenesis and tumor progression. Oncogene. 2014;33:135\u201347.","journal-title":"Oncogene"},{"key":"3482_CR14","doi-asserted-by":"publisher","first-page":"R273","DOI":"10.1677\/ERC-10-0145","volume":"17","author":"RA Taylor","year":"2010","unstructured":"Taylor RA, Toivanen R, Risbridger GP. Stem cells in prostate cancer: treating the root of the problem. Endocr Relat Cancer. 2010;17:R273\u2013285.","journal-title":"Endocr Relat Cancer"},{"key":"3482_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2023.129369","volume":"91","author":"M Castaneda","year":"2023","unstructured":"Castaneda M, Rodriguez L, Oh J, Cagle-White B, Suh H, Abdel Aziz MH, et al. A FOXC2 inhibitor, MC-1-F2, as a therapeutic candidate for targeting EMT in castration-resistant prostate cancer. Bioorg Med Chem Lett. 2023;91:129369.","journal-title":"Bioorg Med Chem Lett"},{"key":"3482_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103370","volume":"163","author":"D Tong","year":"2021","unstructured":"Tong D. Unravelling the molecular mechanisms of prostate cancer evolution from genotype to phenotype. Crit Rev Oncol Hematol. 2021;163:103370.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3482_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.canlet.2021.10.011","volume":"524","author":"V Mugoni","year":"2022","unstructured":"Mugoni V, Ciani Y, Nardella C, Demichelis F. Circulating RNAs in prostate cancer patients. Cancer Lett. 2022;524:57\u201369.","journal-title":"Cancer Lett"},{"key":"3482_CR18","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.semcancer.2020.12.026","volume":"83","author":"A Beilerli","year":"2022","unstructured":"Beilerli A, Gareev I, Beylerli O, Yang G, Pavlov V, Aliev G, et al. Circular RNAs as biomarkers and therapeutic targets in cancer. Semin Cancer Biol. 2022;83:242\u201352.","journal-title":"Semin Cancer Biol"},{"key":"3482_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/978-1-0716-1170-8_5","volume":"2257","author":"AH Alkan","year":"2022","unstructured":"Alkan AH, Akg\u00fcl B. Endogenous miRNA sponges. Methods Mol Biol. 2022;2257:91\u2013104.","journal-title":"Methods Mol Biol"},{"key":"3482_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2024.108711","volume":"263","author":"Q Sun","year":"2024","unstructured":"Sun Q, Lei X, Yang X. CircRNAs as upstream regulators of miRNA\/\/HMGA2 axis in human cancer. Pharmacol Ther. 2024;263:108711.","journal-title":"Pharmacol Ther"},{"key":"3482_CR21","doi-asserted-by":"publisher","first-page":"975","DOI":"10.7150\/ijms.71840","volume":"19","author":"X Zhao","year":"2022","unstructured":"Zhao X, Zhong Y, Wang X, Shen J, An W. Advances in circular RNA and its applications. Int J Med Sci. 2022;19:975\u201385.","journal-title":"Int J Med Sci"},{"key":"3482_CR22","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41580-020-0243-y","volume":"21","author":"LL Chen","year":"2020","unstructured":"Chen LL. The expanding regulatory mechanisms and cellular functions of circular RNAs. Nat Rev Mol Cell Biol. 2020;21:475\u201390.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3482_CR23","first-page":"19","volume":"8","author":"MW Zhang","year":"2021","unstructured":"Zhang MW, Zhu ZH, Xia ZK, Yang X, Luo WT, Ao JH, et al. Comprehensive circRNA-microRNA-mRNA network analysis revealed the novel regulatory mechanism of Trichosporon asahii infection. Mil Med Res. 2021;8:19.","journal-title":"Mil Med Res"},{"key":"3482_CR24","doi-asserted-by":"crossref","unstructured":"Coradduzza D, Cruciani S, Arru C, Garroni G, Pashchenko A, Jedea M et al. Role of miRNA-145, 148, and 185 and stem cells in prostate cancer. Int J Mol Sci. 2022;23:1626.","DOI":"10.3390\/ijms23031626"},{"key":"3482_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14270","volume":"8","author":"C Liu","year":"2017","unstructured":"Liu C, Liu R, Zhang D, Deng Q, Liu B, Chao HP, et al. MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes. Nat Commun. 2017;8:14270.","journal-title":"Nat Commun"},{"key":"3482_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15396-5","volume":"11","author":"K Wang","year":"2020","unstructured":"Wang K, Luo J, Yeh S, You B, Meng J, Chang P, et al. The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer. Nat Commun. 2020;11:2689.","journal-title":"Nat Commun"},{"key":"3482_CR27","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1158\/1078-0432.CCR-13-3296","volume":"20","author":"C Liu","year":"2014","unstructured":"Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP, et al. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clin Cancer Res. 2014;20:3198\u2013210.","journal-title":"Clin Cancer Res"},{"key":"3482_CR28","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/HEP.0000000000000523","volume":"79","author":"H Huang","year":"2024","unstructured":"Huang H, Tsui YM, Ho DW, Chung CY, Sze KM, Lee E, et al. LANCL1, a cell surface protein, promotes liver tumor initiation through FAM49B-Rac1 axis to suppress oxidative stress. Hepatology. 2024;79:323\u201340.","journal-title":"Hepatology"},{"key":"3482_CR29","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1093\/neuonc\/noac157","volume":"25","author":"X Chen","year":"2023","unstructured":"Chen X, Niu W, Fan X, Yang H, Zhao C, Fan J, et al. Oct4A palmitoylation modulates tumorigenicity and stemness in human glioblastoma cells. Neuro Oncol. 2023;25:82\u201396.","journal-title":"Neuro Oncol"},{"key":"3482_CR30","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nn.3975","volume":"18","author":"X You","year":"2015","unstructured":"You X, Vlatkovic I, Babic A, Will T, Epstein I, Tushev G, et al. Neural circular RNAs are derived from synaptic genes and regulated by development and plasticity. Nat Neurosci. 2015;18:603\u201310.","journal-title":"Nat Neurosci"},{"key":"3482_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.523342","volume":"10","author":"S Zhao","year":"2020","unstructured":"Zhao S, Li S, Liu W, Wang Y, Li X, Zhu S, et al. Circular RNA signature in lung adenocarcinoma: a MiOncoCirc database-based study and literature review. Front Oncol. 2020;10:523342.","journal-title":"Front Oncol"},{"key":"3482_CR32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.semcancer.2014.06.004","volume":"31","author":"M Cojoc","year":"2015","unstructured":"Cojoc M, M\u00e4bert K, Muders MH, Dubrovska A. A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms. Semin Cancer Biol. 2015;31:16\u201327.","journal-title":"Semin Cancer Biol"},{"key":"3482_CR33","doi-asserted-by":"publisher","first-page":"8721","DOI":"10.7150\/thno.41648","volume":"10","author":"T Huang","year":"2020","unstructured":"Huang T, Song X, Xu D, Tiek D, Goenka A, Wu B, et al. Stem cell programs in cancer initiation, progression, and therapy resistance. Theranostics. 2020;10:8721\u201343.","journal-title":"Theranostics"},{"key":"3482_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.116781","volume":"234","author":"M Najafi","year":"2019","unstructured":"Najafi M, Mortezaee K, Majidpoor J. Cancer stem cell (CSC) resistance drivers. Life Sci. 2019;234:116781.","journal-title":"Life Sci"},{"key":"3482_CR35","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.canlet.2018.11.004","volume":"444","author":"Y Xiao","year":"2019","unstructured":"Xiao Y, Sun Y, Liu G, Zhao J, Gao Y, Yeh S, et al. Androgen receptor (AR)\/miR-520f-3p\/SOX9 signaling is involved in altering hepatocellular carcinoma (HCC) cell sensitivity to the Sorafenib therapy under hypoxia via increasing cancer stem cells phenotype. Cancer Lett. 2019;444:175\u201387.","journal-title":"Cancer Lett"},{"key":"3482_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2230-9","volume":"11","author":"J Wang","year":"2020","unstructured":"Wang J, Zhao X, Wang Y, Ren F, Sun D, Yan Y, et al. circRNA-002178 act as a ceRNA to promote PDL1\/PD1 expression in lung adenocarcinoma. Cell Death Dis. 2020;11:32.","journal-title":"Cell Death Dis"},{"key":"3482_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-020-07172-y","volume":"21","author":"M Zhao","year":"2020","unstructured":"Zhao M, Qu H. circVAR database: genome-wide archive of genetic variants for human circular RNAs. BMC Genomics. 2020;21:750.","journal-title":"BMC Genomics"},{"key":"3482_CR38","doi-asserted-by":"publisher","first-page":"D92","DOI":"10.1093\/nar\/gkt1248","volume":"42","author":"JH Li","year":"2014","unstructured":"Li JH, Liu S, Zhou H, Qu LH, Yang JH. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014;42:D92\u201397.","journal-title":"Nucleic Acids Res"},{"key":"3482_CR39","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.ebiom.2015.07.017","volume":"2","author":"H Ross-Adams","year":"2015","unstructured":"Ross-Adams H, Lamb AD, Dunning MJ, Halim S, Lindberg J, Massie CM, et al. Integration of copy number and transcriptomics provides risk stratification in prostate cancer: a discovery and validation cohort study. EBioMedicine. 2015;2:1133\u201344.","journal-title":"EBioMedicine"},{"key":"3482_CR40","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/pros.23171","volume":"76","author":"MP Roudier","year":"2016","unstructured":"Roudier MP, Winters BR, Coleman I, Lam HM, Zhang X, Coleman R, et al. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer. Prostate. 2016;76:810\u201322.","journal-title":"Prostate"},{"key":"3482_CR41","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028\u201338.","journal-title":"N Engl J Med"},{"key":"3482_CR42","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1158\/2159-8290.CD-13-0142","volume":"3","author":"M Korpal","year":"2013","unstructured":"Korpal M, Korn JM, Gao X, Rakiec DP, Ruddy DA, Doshi S, et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov. 2013;3:1030\u201343.","journal-title":"Cancer Discov"},{"key":"3482_CR43","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.canlet.2016.05.018","volume":"379","author":"R Wang","year":"2016","unstructured":"Wang R, Lin W, Lin C, Li L, Sun Y, Chang C. ASC-J9(\u00ae) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L. Cancer Lett. 2016;379:154\u201360.","journal-title":"Cancer Lett"},{"key":"3482_CR44","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","volume":"155","author":"VK Arora","year":"2013","unstructured":"Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 2013;155:1309\u201322.","journal-title":"Cell"},{"key":"3482_CR45","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1158\/1535-7163.MCT-13-0027","volume":"12","author":"N Nadiminty","year":"2013","unstructured":"Nadiminty N, Tummala R, Liu C, Yang J, Lou W, Evans CP, et al. NF-\u03baB2\/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Mol Cancer Ther. 2013;12:1629\u201337.","journal-title":"Mol Cancer Ther"},{"key":"3482_CR46","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/pros.22741","volume":"74","author":"C Liu","year":"2014","unstructured":"Liu C, Zhu Y, Lou W, Cui Y, Evans CP, Gao AC. Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells. Prostate. 2014;74:201\u20139.","journal-title":"Prostate"},{"key":"3482_CR47","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1261\/rna.035667.112","volume":"19","author":"WR Jeck","year":"2013","unstructured":"Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. Rna. 2013;19:141\u201357.","journal-title":"Rna"},{"key":"3482_CR48","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nature11993","volume":"495","author":"TB Hansen","year":"2013","unstructured":"Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495:384\u20138.","journal-title":"Nature"},{"key":"3482_CR49","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature11928","volume":"495","author":"S Memczak","year":"2013","unstructured":"Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495:333\u20138.","journal-title":"Nature"},{"key":"3482_CR50","doi-asserted-by":"publisher","first-page":"26680","DOI":"10.18632\/oncotarget.8589","volume":"7","author":"H Xie","year":"2016","unstructured":"Xie H, Ren X, Xin S, Lan X, Lu G, Lin Y, et al. Emerging roles of circRNA_001569 targeting miR-145 in the proliferation and invasion of colorectal cancer. Oncotarget. 2016;7:26680\u201391.","journal-title":"Oncotarget"},{"key":"3482_CR51","doi-asserted-by":"crossref","unstructured":"Morales-Mart\u00ednez M, Vega MI. Role of MicroRNA-7 (MiR-7) in cancer physiopathology. Int J Mol Sci. 2022;23:9091.","DOI":"10.3390\/ijms23169091"},{"key":"3482_CR52","doi-asserted-by":"crossref","unstructured":"Kora\u0107 P, Antica M, Matuli\u0107 M. MiR-7 in cancer development. Biomedicines. 2021;9:325.","DOI":"10.3390\/biomedicines9030325"},{"key":"3482_CR53","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1002\/stem.1795","volume":"32","author":"H Zhang","year":"2014","unstructured":"Zhang H, Cai K, Wang J, Wang X, Cheng K, Shi F, et al. MiR-7, inhibited indirectly by lincRNA HOTAIR, directly inhibits SETDB1 and reverses the EMT of breast cancer stem cells by downregulating the STAT3 pathway. Stem Cells. 2014;32:2858\u201368.","journal-title":"Stem Cells"},{"key":"3482_CR54","doi-asserted-by":"publisher","first-page":"24017","DOI":"10.18632\/oncotarget.4447","volume":"6","author":"YL Chang","year":"2015","unstructured":"Chang YL, Zhou PJ, Wei L, Li W, Ji Z, Fang YX, et al. MicroRNA-7 inhibits the stemness of prostate cancer stem-like cells and tumorigenesis by repressing KLF4\/PI3K\/Akt\/p21 pathway. Oncotarget. 2015;6:24017\u201331.","journal-title":"Oncotarget"},{"key":"3482_CR55","doi-asserted-by":"crossref","unstructured":"Li WJ, Wang Y, Liu X, Wu S, Wang M, Turowski SG et al. Developing folate-conjugated miR-34a therapeutic for prostate cancer: challenges and promises. Int J Mol Sci. 2024;25:2123.","DOI":"10.3390\/ijms25042123"},{"key":"3482_CR56","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1002\/stem.101","volume":"27","author":"D Kong","year":"2009","unstructured":"Kong D, Li Y, Wang Z, Banerjee S, Ahmad A, Kim HR, et al. miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells. 2009;27:1712\u201321.","journal-title":"Stem Cells"},{"key":"3482_CR57","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.canlet.2016.03.008","volume":"375","author":"M Ampuja","year":"2016","unstructured":"Ampuja M, Alarmo EL, Owens P, Havunen R, Gorska AE, Moses HL, et al. The impact of bone morphogenetic protein 4 (BMP4) on breast cancer metastasis in a mouse xenograft model. Cancer Lett. 2016;375:238\u201344.","journal-title":"Cancer Lett"},{"key":"3482_CR58","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.canlet.2016.12.042","volume":"390","author":"S Zeng","year":"2017","unstructured":"Zeng S, Zhang Y, Ma J, Deng G, Qu Y, Guo C, et al. BMP4 promotes metastasis of hepatocellular carcinoma by an induction of epithelial-mesenchymal transition via upregulating ID2. Cancer Lett. 2017;390:67\u201376.","journal-title":"Cancer Lett"},{"key":"3482_CR59","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1002\/ijc.28734","volume":"135","author":"WT Fang","year":"2014","unstructured":"Fang WT, Fan CC, Li SM, Jang TH, Lin HP, Shih NY, et al. Downregulation of a putative tumor suppressor BMP4 by SOX2 promotes growth of lung squamous cell carcinoma. Int J Cancer. 2014;135:809\u201319.","journal-title":"Int J Cancer"},{"key":"3482_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-021-00310-5","volume":"10","author":"G Yan","year":"2021","unstructured":"Yan G, Dai M, Zhang C, Poulet S, Moamer A, Wang N, et al. TGF\u03b2\/cyclin D1\/Smad-mediated inhibition of BMP4 promotes breast cancer stem cell self-renewal activity. Oncogenesis. 2021;10:21.","journal-title":"Oncogenesis"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03482-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03482-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03482-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T01:09:43Z","timestamp":1757207383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03482-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":60,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2025,9,15]]}},"alternative-id":["3482"],"URL":"https:\/\/doi.org\/10.1038\/s41388-025-03482-1","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,4]]},"assertion":[{"value":"21 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal care and use procedures were performed according to the Principles of Animal Care provided by the National Society for Medical Research and the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, NIH). All the animal experiments were approved by the ethics committee of Fourth Affiliated Hospital of Harbin Medical University(approval number: 2024-DWSYLLCZ-29). All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}